ProCE Banner Activity

BELIEVE: Phase III Study of Luspatercept vs Placebo in Beta-Thalassemia

Slideset Download
Conference Coverage

Transfusion-dependent adults with beta-thalassemia who received luspatercept were more likely to achieve clinically meaningful reductions in transfusion burden compared with placebo.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Celgene

Dova Pharmaceuticals

Gilead Text

Incyte

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals, Inc.

Novartis Pharmaceuticals Corporation

Seagen

Takeda Oncology